好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

ChatGPT as Clinical Decision-Making Tool for Headache Screening
Headache
P4 - Poster Session 4 (5:00 PM-6:00 PM)
12-009

This study evaluates ChatGPT-4’s ability to differentiate between primary and secondary headaches using the SNNOOP10 criteria.

Headaches are a prevalent issue, accounting for 3.5 million annual emergency department (ED) visits in the United States. They are classified into primary and secondary headaches, with secondary headaches potentially indicating serious underlying conditions. The SNNOOP10 mnemonic helps screen for red flags suggesting secondary headaches. Artificial Intelligence (AI) algorithms have shown promise in assisting with patient triage in EDs and primary care settings.

Two ChatGPT-4 AI chatbots, Microsoft Bing Copilot and OpenAI, were tested with 60 artificial headache scenarios—30 primary and 30 secondary. Each AI was primed to classify the headaches based on SNNOOP10 criteria. The explanations provided by the chatbots were screened for errors and categorized into clinical reasoning, hallucinations, logic, math, misdiagnosis, and misinterpretation.

Bing Copilot and OpenAI both correctly classified 59 out of 60 cases (98%) using SNNOOP10 criteria. Each system made an error in classifying the primary headache scenarios. Interestingly, the errors occurred in different scenarios. Bing Copilot had 9 explanation errors, while OpenAI had 7.

Both chatbots demonstrated near-perfect accuracy in classifying headaches using SNNOOP10 criteria, showing particular sensitivity to secondary headaches, which often require urgent evaluation. However, the higher number of explanation errors made by chatbots highlight the need for improvements in clinical reasoning. Despite these errors, ChatGPT shows promise as an initial tool for differentiating secondary from primary headaches, potentially aiding in urgent evaluations for serious conditions.

Authors/Disclosures
Aizara Ermekbaeva, MD
PRESENTER
Ms. Ermekbaeva has nothing to disclose.
Tse Chiang Chen, MD (Tulane School of Medicine) Dr. Chen has nothing to disclose.
Mei Yang, MD (Tulane University School of Medicine) Dr. Yang has nothing to disclose.
Amy Urbina Mrs. Urbina has nothing to disclose.
Alireza Shirazian, MD (Tulane Neurology Residency) Dr. Shirazian has nothing to disclose.
Nimmi N. Wickramasuriya, MD (Tulane University Hospital and Clinics) Dr. Wickramasuriya has nothing to disclose.
Jonathan P. Rodriguez, MBBS (Tulane Medical Center) Mr. Rodriguez has nothing to disclose.
Michele Longo, MD, MPH, FAAN Dr. Longo has received research support from National Institute of Health.